

## **Neopharma Technologies launch the World's First Integration of a Rapid Drug Test with Cognitive Impairment Technology using DRUID**

**FOR IMMEDIATE RELEASE: September 5, 2024**

Media Contact: Robert Schiller, CEO, 617-955-7862, [rob@impairmentscience.com](mailto:rob@impairmentscience.com)

**Cambridge, MA** –Impairment Science, Inc. is thrilled to announce a groundbreaking partnership with Neopharma Technologies to introduce the world's first integration of a rapid drug test with cognitive impairment technology. This innovative solution addresses the growing demand for efficient and objective impairment measurement in the workplace and on the roadside.

Designed, in this era of cannabis legalization, specifically for employers grappling with the complexities of THC testing, this cutting-edge combination of technologies offers a dual advantage: it not only tests for the presence of drugs, including THC, but also provides a rapid, accurate, objective assessment of cognitive impairment. By combining these functions, this new combination is a powerful employee retention tool, streamlining the hiring process, while reducing costs associated with traditional drug testing methods.

As the trend shifts from pre-employment drug testing to continuous workplace monitoring, Neopharma Technologies' and Impairment Science's solution stands out as the only tool on the market offering dual capabilities. Testing is effected through a user-friendly app, requiring no additional equipment for measuring and recording results. This integration enhances accuracy and efficiency, providing employers with a reliable method to ensure a safe and productive work environment.

"Our partnership with Impairment Science marks a significant milestone in our commitment to innovation, uniquely addressing the evolving needs of employers," said Nina French, CEO of Neopharma Technologies. "This combination of technologies is set to transform the way employers approach drug testing and impairment assessment, ultimately improving workplace safety and operational efficiency."

"Marrying drug testing with impairment testing will identify those who pose a risk to themselves, their co-workers, and their employer in a way that drug testing, alone, cannot do. We are delighted to be part of this significant expansion of the capability to enhance safety and productivity," said Rob Schiller, CEO of Impairment Science, Inc.

For more information about this revolutionary product and how it can benefit your organization, please visit [www.neopharmatechnologies.com](http://www.neopharmatechnologies.com) or contact [enquiries@neopharmatechnologies.com](mailto:enquiries@neopharmatechnologies.com).

### **About Neopharma Technologies:**

Neopharma Technologies, LTD., dedicated to developing cutting-edge solutions that address pressing industry needs, has created the next generation of drug testing. Our commitment to advancing technology and improving efficiency drives our mission to deliver exceptional products and services.

# IMPAIRMENT SCIENCE, INC.

1035 Cambridge Street  
Cambridge, MA 02141

## **About Impairment Science:**

Impairment Science specializes in cognitive impairment technologies, providing solutions including DRUID, its fit-for-duty app, that enhance workplace safety and productivity. Our innovative approach, using neuroscience, ensures rapid, accurate, objective, assessment of cognitive function, supporting a safer, less costly work environment.

Learn more at [www.impairmentscience.com](http://www.impairmentscience.com).

###